# A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

> **NCT01874288** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alopexx Oncology, LLC** · enrollment: 24 (actual)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** DI-Leu16-IL2

## Key facts

- **NCT ID:** NCT01874288
- **Lead sponsor:** Alopexx Oncology, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-25
- **Primary completion:** 2014-01-27
- **Final completion:** 2016-11-16
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874288, "A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01874288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*